Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Immunogenicity of BNT162b2 mRNA-Based Vaccine against SARS-CoV-2 in People with Cystic Fibrosis

Gianfranco Alicandro
* ORCID logo ,
Valeria Daccò
,
Lisa Cariani
,
Chiara Rosazza
,
Calogero Sathyà Sciarrabba
,
Federica Ferraro
,
Chiara Lanfranchi
,
Paola Medino
,
Daniela Girelli
,
Carla Colombo
* ORCID logo
Version 1 : Received: 26 July 2022 / Approved: 27 July 2022 / Online: 27 July 2022 (13:29:14 CEST)

How to cite: Alicandro, G.; Daccò, V.; Cariani, L.; Rosazza, C.; Sciarrabba, C.S.; Ferraro, F.; Lanfranchi, C.; Medino, P.; Girelli, D.; Colombo, C. Immunogenicity of BNT162b2 mRNA-Based Vaccine against SARS-CoV-2 in People with Cystic Fibrosis. Preprints 2022, 2022070422. https://doi.org/10.20944/preprints202207.0422.v1 Alicandro, G.; Daccò, V.; Cariani, L.; Rosazza, C.; Sciarrabba, C.S.; Ferraro, F.; Lanfranchi, C.; Medino, P.; Girelli, D.; Colombo, C. Immunogenicity of BNT162b2 mRNA-Based Vaccine against SARS-CoV-2 in People with Cystic Fibrosis. Preprints 2022, 2022070422. https://doi.org/10.20944/preprints202207.0422.v1

Abstract

During the SARS-CoV-2 vaccination campaign, people with CF (pwCF) were considered a clinically vulnerable population. However, data on immunogenicity of anti-SARS-CoV-2 vaccines in pwCF are lacking. We conducted a prospective study enrolling all patients aged >12 and followed-up in our CF centre, who received two doses of the BNT162b2 vaccine in March-­­­October 2021. They underwent a blood sample for quantification of antibodies to the SARS-CoV-2 spike protein receptor binding domain immediately before receiving the first dose and after 3 and 6 months from the second dose. We enrolled 143 patients (median age: 21 years, range: 13-38); of whom 16 had a previous infection. Median antibody titer (interquartile range) after 3 months from vaccination was 1288 U/mL (730-2115) and decreased to 918 U/mL (534-1488) after 6 months (P<0.0001). Median values were higher among previously infected patients as compared to those naïve to SARS-CoV-2 (9107 vs 1229 U/mL at 3 months and 4810 vs 829 U/mL at 6 months, P<0.0001) with no significant differences in the rate of decline over time (P=0.135). All pwCF mounted an antibody response after two-doses of BNT162b2 vaccine that waned at 6 months from vaccination. Age ≥30 years and use of inhaled corticosteroids were associated with a lower humoral response.

Keywords

cystic fibrosis; SARS-CoV-2; Covid-19, vaccine; antibody response; humoral response

Subject

Biology and Life Sciences, Immunology and Microbiology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF Download Supplementary

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Supplementary Files Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.